Abstract
Extensive-stage small cell lung cancer is an aggressive malignancy with historically poor survival outcomes. At JADPRO Live, presenters highlighted recent advances that are reshaping the management of this disease. Practical guidance focused on recognizing and managing oncologic emergencies, chemotherapy-related toxicities, immune-related adverse events, and novel toxicities associated with bispecific T-cell engagers, with a focus on patient and caregiver education.
